Developmental differences in megakaryocyte size in infants and children.
Am. J. Clin. Pathol., Jul;138(1):140-5 (2012)
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.
Blood., Feb;119(6):1459-67 (2012)
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Haematologica., Jun;97(6):937-42 (2012)
Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
Clin. Cancer Res., Jun;17(11):3727-32 (2011)
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.
Haematologica., Apr;95(4):597-603 (2010)
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
Leuk. Lymphoma., May;50(5):728-35 (2009)
HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen.
Leuk. Lymphoma., Mar;48(3):542-6 (2007)
Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma.
Lab. Invest., Oct;87(10):979-97 (2007)
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.
Blood., Nov;106(10):3594-601 (2005)
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.
Blood., Feb;107(3):1101-7 (2006)
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.
Blood., Jul;108(1):311-8 (2006)
Benign B-cell precursors (hematogones) are the predominant lymphoid population in the bone marrow of preterm infants.
Biol. Neonate., 86(4):247-53 (2004)
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular
Blood., Jun;103(11):4251-8 (2004)
Rapid automated combined in situ hybridization and immunohistochemistry for sensitive detection of cytomegalovirus in paraffin-embedded tissue biopsies.
Am. J. Clin. Pathol., Oct;106(4):544-8 (1996)
Lack and/or aberrant localization of major histocompatibility Class II (MHCII)protein in plasmablastic lymphoma.
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
Blood., Aug;120(6):1210-7 (2012)
Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
Arch. Pathol. Lab. Med., Dec;130(12):1819-24 (2006)
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
J. Clin. Oncol., May;26(14):2258-63 (2008)